Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH1110760852
Tue, 12.03.2024
PolyPeptide Group
Media release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow
Baar, 12 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical in [ … ]
Tue, 15.08.2023
PolyPeptide Group
Media release – ad hoc announcement pursuant to Art. 53 LR
Transformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO
Baar, 15 August 2023 – PolyPeptide today announced its results for H1 2023, updated guidance for 2023 and the appointment of its new CFO:
Reported re [ … ]
Thu, 13.07.2023
PolyPeptide Group
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023
Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide business. It expects 2023 to be [ … ]
Thu, 13.07.2023
PolyPeptide Group
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023
Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide business. It expects 2023 to be [ … ]
Mon, 03.04.2023
PolyPeptide Group
Media release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO
Baar, 3 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of Jua [ … ]
Mon, 03.04.2023
PolyPeptide Group
Media release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO
Baar, 3 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of Jua [ … ]
Tue, 14.03.2023
PolyPeptide
Media release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023
Baar, 14 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its [ … ]
Tue, 14.03.2023
PolyPeptide
Media release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023
Baar, 14 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its [ … ]
Mon, 30.01.2023
PolyPeptide
Media Release – ad hoc announcement pursuant to Art. 53 LR
CEO of PolyPeptide resigns
Baar, 30 January 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the resignation by its CEO Raymond De Vré.
Raymond De Vré, CEO [ … ]
Mon, 19.12.2022
PolyPeptide
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide signs significant commercial agreement
Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a significant commercial a [ … ]